Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

Document Sample
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies Powered By Docstoc
					Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to
Trigger a Shift in Treatment Paradigm to Targeted Therapies


 GBI Research, the leading business intelligence provider, has released its latest research: Solid Tumors in
Asia-Pacific Market to 2019 - New and Anticipated Approvals of Targeted Therapies to Trigger a Shift in
Treatment Paradigm, which provides in-depth analysis of four key therapeutic indications within the
Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and
prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides
an estimation of market size for 2012, along with market forecast until 2019. It also covers disease
epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for
these four solid tumor types.
 The value of the solid tumors market in the APAC region amounted to an estimated $1 billion in 2012 and is
expected to register a modest Compound Annual Growth Rate (CAGR) of 12.3% to reach $2.3 billion in 2019.
The key drivers for growth in this market include: new product approvals in ovarian, pancreatic and prostate
cancers; expected launches from the promising ovarian and prostate cancer pipelines; and increased market
penetration due to the anticipated implementation of social insurance in China. Conversely, the growth of the
market in this region could face some restricting influences, including: the recent implementation of a price
ceiling on essential drugs in India; anticipated pricing restrictions in China; low access and penetration; and
price erosion due to generic competition. Scope
 The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and
co-development deals in the bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer in the four
APAC markets of Australia, China, India and Japan.
 The report includes:
  Disease overview, as well as treatment algorithms and treatment usage patterns Market size and forecast for
the APAC solid tumors market from 2012 to 2019 Major marketed products in the APAC region for all four
solid tumor types covered In-depth pipeline analysis for all four solid tumor types Key drivers and restraints
that have had and are expected to have a significant impact upon the market Key licensing and
co-development agreements in the solid tumors market
 Reasons to Buy
 The report will enhance your decision-making capability by allowing you to:
  Align your product portfolio to the markets with high growth potential Develop market entry and expansion
strategies by identifying the potential regions and therapeutic segments poised for strong growth Devise a
more effectively tailored country strategy through the understanding of key drivers and barriers in the solid
tumors market Develop key strategic initiatives based upon an understanding of key focus areas and leading
companies Accelerate and strengthen your market position by identifying key companies for mergers,
acquisitions and strategic partnerships

table Of Content




Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
1 Table Of Contents
1.1 List Of Tables
1.2 List Of Figures


2 Solid Tumors Market In Asia Pacific To 2019 - Introduction
2.1 Introduction


3 Solid Tumors Market In Asia Pacific To 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Diagnosis
3.1.5 Classification
3.1.6 Epidemiology
3.1.7 Prognosis And Disease Staging
3.1.8 Treatment Options
3.2 Ovarian Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Diagnosis
3.2.5 Classification
3.2.6 Epidemiology
3.2.7 Prognosis And Disease Staging
3.2.8 Treatment Options
3.3 Pancreatic Cancer
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Classification
3.3.6 Epidemiology
3.3.7 Prognosis And Disease Staging
3.3.8 Treatment Algorithm
3.4 Prostate Cancer
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-morbidities And Complications
3.4.5 Diagnosis

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
3.4.6 Classification
3.4.7 Epidemiology
3.4.8 Prognosis And Disease Staging
3.4.9 Treatment Options


4 Solid Tumors Market In Asia Pacific To 2019 - Marketed Products
4.1 Bladder Cancer
4.2 Ovarian Cancer
4.3 Pancreatic Cancer
4.4 Prostate Cancer
4.5 Key Marketed Products
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 Doxorubicin
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone Acetate)
4.5.12 Jevtana (cabazitaxel)


5 Solid Tumors Market In Asia Pacific To 2019 - Pipeline Analysis
5.1 Bladder Cancer Pipeline
5.1.1 Overall Pipeline
5.1.2 Pipeline Analysis By Molecule Type
5.1.3 Pipeline Analysis By Mechanism Of Action
5.2 Ovarian Cancer Pipeline
5.2.1 Overall Pipeline
5.2.2 Pipeline Analysis By Molecule Type
5.2.3 Pipeline Analysis By Mechanism Of Action
5.3 Pancreatic Cancer Pipeline
5.3.1 Overall Pipeline
5.3.2 Pipeline Analysis By Molecule Type
5.3.3 Pipeline Analysis By Mechanism Of Action
5.4 Prostate Cancer Pipeline
5.4.1 Overall Pipeline
5.4.2 Pipeline Analysis By Molecule Type
5.4.3 Pipeline Analysis By Mechanism Of Action

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
5.5 Promising Drug Candidates In The Pipeline
5.5.1 Abraxane (albumin-bound Paclitaxel)
5.5.2 Amg 386 (trebananib)
5.5.3 Votrient (pazopanib)
5.5.4 Xtandi (enzalutamide)


6 Solid Tumors Market In Asia Pacific To 2019- Market Forecast
6.1 Asia-pacific Market
6.1.1 Treatment Usage Patterns
6.1.2 Annual Cost Of Treatment
6.1.3 Market Size
6.2 India
6.2.1 Treatment Usage Patterns
6.2.2 Annual Cost Of Treatment
6.2.3 Market Size
6.3 Australia
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost Of Treatment
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost Of Treatment
6.4.3 Market Size
6.5 Japan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost Of Treatment
6.5.3 Market Size
6.6 Drivers And Barriers For The Solid Tumors Market In Apac
6.6.1 Drivers
6.6.2 Barriers


7 Solid Tumors Market In Asia Pacific To 2019 - Deals And Strategic Consolidations
7.1 Deals Analysis
7.2 Major Co-development Deals
7.2.1 Scinopharm Taiwan And Coland Enter Into Agreement To Develop Generic Oncological Drugs
7.2.2 Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs
7.2.3 Merck Enters Into Co-development Agreement With Endocyte For Cancer Drug
7.2.4 Merck Serono Enters Into Co-development Agreement With Threshold Pharma For Th-302,
pancreatic Cancer Drug
7.2.5 Seattle Genetics Exercises Option For Co-development Agreement With Agensys (affiliate Of
astellas) For Asg-15me

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
7.3 Major Licensing Deals
7.3.1 Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone
7.3.2 Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For Ff284
7.3.3 Baxter International Enters Into Licensing Agreement With Onconova Therapeutics For
rigosertib
7.3.4 Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug
7.3.5 Medigene Extends Licensing Agreement With Syncore For Endotag-1


8 Solid Tumors Market In Asia Pacific To 2019 - Appendix
8.1 Pipeline Drugs By Phase
8.1.1 Phase Iii
8.1.2 Pre-registration/nda-filed
8.2 Market Forecasts To 2018
8.2.1 Apac
8.2.2 Australia
8.2.3 China
8.2.4 India
8.2.5 Japan
8.3 Market Definitions
8.4 Abbreviations
8.5 Sources
8.6 Research Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Primary Research
8.6.4 Therapeutic Landscape
8.6.5 Geographical Landscape
8.6.6 Pipeline Analysis
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer

ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.

Contact:
M/s Sheela,
90 State Street,

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/



Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:0
posted:9/23/2013
language:English
pages:6